Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Malaria - Pipeline Review, H2 2011

VIEWS: 3 PAGES: 147

Malaria - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Malaria - Pipeline Review, H2 2011', provides an overview of the Malaria therapeutic pipeline. This report provides information on the therapeutic development for Malaria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malaria. 'Malaria - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Malaria. - A review of the Malaria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Malaria pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Malaria. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by

More Info
									Malaria – Pipeline Review, H2 2011




                                  Malaria - Pipeline Review, H2 2011
                                                                                          Reference Code: GMDHC1460IDB

                                                                                          Publication Date: October 2011




Malaria – Pipeline Review, H2 2011                                                                               GMDHC1460IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                  Page(1)
Malaria – Pipeline Review, H2 2011



Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 9
      List of Figures ...................................................................................................................................................................................................11
Introduction .............................................................................................................................................................................................................12
      Global Markets Direct Report Coverage ............................................................................................................................................................12
Malaria Overview.....................................................................................................................................................................................................13
Therapeutics Development ......................................................................................................................................................................................14
      An Overview of Pipeline Products for Malaria ....................................................................................................................................................14
Malaria Therapeutics under Development by Companies ........................................................................................................................................16
Malaria Therapeutics under Investigation by Universities/Institutes..........................................................................................................................19
Late Stage Products ................................................................................................................................................................................................23
      Comparative Analysis .......................................................................................................................................................................................23
Mid Clinical Stage Products .....................................................................................................................................................................................24
      Comparative Analysis .......................................................................................................................................................................................24
Early Clinical Stage Products ..................................................................................................................................................................................25
      Comparative Analysis .......................................................................................................................................................................................25
Discovery and Pre-Clinical Stage Products..............................................................................................................................................................26
      Comparative Analysis .......................................................................................................................................................................................26
Malaria Therapeutics - Products under Development by Companies .......................................................................................................................27
Malaria Therapeutics - Products under Investigation by Universities/Institutes.........................................................................................................31
Companies Involved in Malaria Therapeutics Development .....................................................................................................................................39
      Johnson & Johnson...........................................................................................................................................................................................39
      Sanofi-Aventis ...................................................................................................................................................................................................39
      GlaxoSmithKline plc ..........................................................................................................................................................................................40
      Inovio Biomedical Corporation...........................................................................................................................................................................40
      Eastland Medical Systems Limited ....................................................................................................................................................................41
      Novartis AG.......................................................................................................................................................................................................41
      Pfizer Inc. ..........................................................................................................................................................................................................42
      Ranbaxy Laboratories Limited ...........................................................................................................................................................................42
      Sigma-Tau S.p.A. ..............................................................................................................................................................................................43
      Aduro BioTech ..................................................................................................................................................................................................43
      Optimer Pharmaceuticals, Inc. ..........................................................................................................................................................................43
      Paratek Pharmaceuticals, Inc. ...........................................................................................................................................................................44
      Mymetics Corporation .......................................................................................................................................................................................44
      Patrys Limited ...................................................................................................................................................................................................45
      Alnylam Pharmaceuticals, Inc ...........................................................................................................................................................................45
      Lipoxen PLC .....................................................................................................................................................................................................46
      Cytos Biotechnology AG ...................................................................................................................................................................................46
      Sinobiomed, Inc. ...............................................................................................................................................................................................47
      PolyMedix, Inc...................................................................................................................................................................................................47
      Affitech A/S .......................................................................................................................................................................................................48
      Bharat Biotech International Limited ..................................................................................................................................................................48
      Jenrin Discovery, Inc. ........................................................................................................................................................................................49
      Anacor Pharmaceuticals, Inc. ............................................................................................................................................................................49
      Telormedix SA ..................................................................................................................................................................................................50
      Treague Ltd ......................................................................................................................................................................................................50
      Dilafor AB..........................................................................................................................................................................................................51


Malaria – Pipeline Review, H2 2011                                                                                                                             GMDHC1460IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                                                 Page(2)
Malaria – Pipeline Review, H2 2011


      Okairos .............................................................................................................................................................................................................51
      Sanaria Inc. .......................................................................................................................................................................................................51
      NovaLead Pharma Pvt. Ltd. ..............................................................................................................................................................................52
      Juvaris BioTherapeutics, Inc. ............................................................................................................................................................................52
      Etubics Corporation...........................................................................................................................................................................................53
      iBio, Inc. ............................................................................................................................................................................................................53
      PepTcell Limited ...............................................................................................................................................................................................53
      Genocea Biosciences, Inc. ................................................................................................................................................................................54
      PALUMED S.A. .................................................................................................................................................................................................54
      Jomaa Pharma GmbH.......................................................................................................................................................................................55
      Shanghai Wanxing Bio-Pharmaceutical Co. Ltd. ...............................................................................................................................................55
Malaria - Therapeutics Assessment .........................................................................................................................................................................56
      Assessment by Monotherapy Products .............................................................................................................................................................56
      Assessment by Combination Products ..............................................................................................................................................................57
      Assessment by Route of Administration ............................................................................................................................................................58
      Assessment by Molecule Type ..........................................................................................................................................................................61
Drug Profiles ...........................................................................................................................................................................................................63
      ArTiMist - Drug Profile .......................................................................................................................................................................................63
            Product Description ....................................................................................................................................................................................63
            Mechanism of Action...................................................................................................................................................................................63
            R&D Progress .............................................................................................................................................................................................63
      Nuartez - Drug Profile .......................................................................................................................................................................................64
            Product Description ....................................................................................................................................................................................64
            Mechanism of Action...................................................................................................................................................................................64
            R&D Progress .............................................................................................................................................................................................64
      Pyramax - Drug Profile ......................................................................................................................................................................................65
            Product Description ....................................................................................................................................................................................65
            Mechanism of Action...................................................................................................................................................................................65
            R&D Progress .............................................................................................................................................................................................65
      Eurartesim - Drug Profile ...................................................................................................................................................................................66
            Product Description ....................................................................................................................................................................................66
            Mechanism of Action...................................................................................................................................................................................66
            R&D Progress .............................................................................................................................................................................................66
      RBx11160 - Drug Profile ...................................................................................................................................................................................67
            Product Description ....................................................................................................................................................................................67
            Mechanism of Action...................................................................................................................................................................................67
            R&D Progress .............................................................................................................................................................................................67
      Sulphadoxine + Pyrimethamine + Mefloquine + Chlorproguanil + Dapsone - Drug Profile .................................................................................69
            Product Description ....................................................................................................................................................................................69
            Mechanism of Action...................................................................................................................................................................................69
            R&D Progress .............................................................................................................................................................................................69
      Artesunate + Mefloquine - Drug Profile..............................................................................................................................................................71
            Product Description ....................................................................................................................................................................................71
            Mechanism of Action...................................................................................................................................................................................71
            R&D Progress .............................................................................................................................................................................................71
      Amodiaquine + Artesunate - Drug Profile ..........................................................................................................................................................72
            Product Description ....................................................................................................................................................................................72
            Mechanism of Action...................................................................................................................................................................................72




Malaria – Pipeline Review, H2 2011                                                                                                                              GMDHC1460IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                                                  Page(3)
Malaria – Pipeline Review, H2 2011


          R&D Progress .............................................................................................................................................................................................72
     Coartem - Drug Profile ......................................................................................................................................................................................73
          Product Description ....................................................................................................................................................................................73
          Mechanism of Action...................................................................................................................................................................................73
          R&D Progress .............................................................................................................................................................................................73
     Amodiaquine + Artesunate - Drug Profile ..........................................................................................................................................................74
          Product Description ....................................................................................................................................................................................74
          Mechanism of Action...................................................................................................................................................................................74
          R&D Progress .............................................................................................................................................................................................74
     Artemether + Lumefantrine - Drug Profile ..........................................................................................................................................................75
          Product Description ....................................................................................................................................................................................75
          Mechanism of Action...................................................................................................................................................................................75
          R&D Progress .............................................................................................................................................................................................75
     Amodiaquine + Sulfadoxine + Pyrimethamine - Drug Profile..............................................................................................................................76
          Product Description ....................................................................................................................................................................................76
          Mechanism of Action...................................................................................................................................................................................76
          R&D Progress .............................................................................................................................................................................................76
     Amodiaquine + Artesunate - Drug Profile ..........................................................................................................................................................77
          Product Description ....................................................................................................................................................................................77
          Mechanism of Action...................................................................................................................................................................................77
          R&D Progress .............................................................................................................................................................................................77
     Artekin - Drug Profile .........................................................................................................................................................................................79
          Product Description ....................................................................................................................................................................................79
          Mechanism of Action...................................................................................................................................................................................79
          R&D Progress .............................................................................................................................................................................................79
     20% Diethyltoluamide - Drug Profile ..................................................................................................................................................................81
          Product Description ....................................................................................................................................................................................81
          Mechanism of Action...................................................................................................................................................................................81
          R&D Progress .............................................................................................................................................................................................81
     Artemether + Lumefantrine - Drug Profile ..........................................................................................................................................................82
          Product Description ....................................................................................................................................................................................82
          Mechanism of Action...................................................................................................................................................................................82
          R&D Progress .............................................................................................................................................................................................82
     Lapdap + Arsumax - Drug Profile ......................................................................................................................................................................83
          Product Description ....................................................................................................................................................................................83
          Mechanism of Action...................................................................................................................................................................................83
          R&D Progress .............................................................................................................................................................................................83
     Chloroquine for Vivax Malaria - Drug Profile ......................................................................................................................................................84
          Product Description ....................................................................................................................................................................................84
          Mechanism of Action...................................................................................................................................................................................84
          R&D Progress .............................................................................................................................................................................................84
     Chloroquine + Primaquine - Drug Profile ...........................................................................................................................................................85
          Product Description ....................................................................................................................................................................................85
          Mechanism of Action...................................................................................................................................................................................85
          R&D Progress .............................................................................................................................................................................................85
     Primaquine - Drug Profile ..................................................................................................................................................................................86
          Product Description ....................................................................................................................................................................................86
          Mechanism of Action...................................................................................................................................................................................86




Malaria – Pipeline Review, H2 2011                                                                                                                        GMDHC1460IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                                          Page(4)
Malaria – Pipeline Review, H2 2011


          R&D Progress .............................................................................................................................................................................................86
     Amodiaquine + Sulfadoxine + Pyrimethamine - Drug Profile..............................................................................................................................87
          Product Description ....................................................................................................................................................................................87
          Mechanism of Action...................................................................................................................................................................................87
          R&D Progress .............................................................................................................................................................................................87
     Artemether - Drug Profile ..................................................................................................................................................................................88
          Product Description ....................................................................................................................................................................................88
          Mechanism of Action...................................................................................................................................................................................88
          R&D Progress .............................................................................................................................................................................................88
     Zithromax + Aralen - Drug Profile ......................................................................................................................................................................89
          Product Description ....................................................................................................................................................................................89
          Mechanism of Action...................................................................................................................................................................................89
          R&D Progress .............................................................................................................................................................................................89
     Sulfadoxine + Pyrimethamine - Drug Profile ......................................................................................................................................................90
          Product Description ....................................................................................................................................................................................90
          Mechanism of Action...................................................................................................................................................................................90
          R&D Progress .............................................................................................................................................................................................90
     Artesunate + Mefloquine - Drug Profile..............................................................................................................................................................91
          Product Description ....................................................................................................................................................................................91
          Mechanism of Action...................................................................................................................................................................................91
          R&D Progress .............................................................................................................................................................................................91
     Artekin - Drug Profile .........................................................................................................................................................................................92
          Product Description ....................................................................................................................................................................................92
          Mechanism of Action...................................................................................................................................................................................92
          R&D Progress .............................................................................................................................................................................................92
     Trimethoprim + Sulfamethoxazole - Drug Profile ...............................................................................................................................................93
          Product Description ....................................................................................................................................................................................93
          Mechanism of Action...................................................................................................................................................................................93
          R&D Progress .............................................................................................................................................................................................93
     Sulfadoxine + Pyrimethamine - Drug Profile ......................................................................................................................................................95
          Product Description ....................................................................................................................................................................................95
          Mechanism of Action...................................................................................................................................................................................95
          R&D Progress .............................................................................................................................................................................................95
     Dihydroartemisinin + Piperaquine - Drug Profile ................................................................................................................................................97
          Product Description ....................................................................................................................................................................................97
          Mechanism of Action...................................................................................................................................................................................97
          R&D Progress .............................................................................................................................................................................................97
     Lopinavir + Ritonavir + Zidovudine + Lamivudine - Drug Profile.........................................................................................................................99
          Product Description ....................................................................................................................................................................................99
          Mechanism of Action...................................................................................................................................................................................99
          R&D Progress .............................................................................................................................................................................................99
     Mosquirix - Drug Profile ...................................................................................................................................................................................101
          Product Description ..................................................................................................................................................................................101
          Mechanism of Action.................................................................................................................................................................................101
          R&D Progress ...................................
								
To top